25.43
2.86%
-0.75
Pre-market:
25.37
-0.06
-0.24%
Enliven Therapeutics Inc stock is traded at $25.43, with a volume of 151.05K.
It is down -2.86% in the last 24 hours and down -12.31% over the past month.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
See More
Previous Close:
$26.18
Open:
$26.25
24h Volume:
151.05K
Relative Volume:
0.62
Market Cap:
$1.24B
Revenue:
-
Net Income/Loss:
$-82.83M
P/E Ratio:
-20.49
EPS:
-1.2413
Net Cash Flow:
$-72.22M
1W Performance:
-1.43%
1M Performance:
-12.31%
6M Performance:
+5.96%
1Y Performance:
+141.27%
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ELVN | 25.43 | 1.24B | 0 | -82.83M | -72.22M | -1.2413 |
VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-29-23 | Initiated | Jefferies | Buy |
Enliven Therapeutics Inc Stock (ELVN) Latest News
Short Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Increases By 6.1% - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by First Turn Management LLC - MarketBeat
Robert W. Baird Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price - Defense World
Enliven Therapeutics has cash runway into late 2026 - BizWest
Robert W. Baird Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
RA Capital Management, L.P. Reduces Stake in Enliven Therapeutics Inc. - GuruFocus.com
Citadel Advisors LLC Adjusts Stake in Enliven Therapeutics Inc - GuruFocus.com
COMMODORE CAPITAL LP Expands Stake in Enliven Therapeutics Inc - GuruFocus.com
Enliven Therapeutics Reports Q3 Results and Clinical Progress - TipRanks
Polar Capital Holdings Plc's Strategic Acquisition in Enliven Th - GuruFocus.com
Enliven Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
(ELVN) Investment Analysis and Advice - Stock Traders Daily
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference - StockTitan
How to Take Advantage of moves in (ELVN) - Stock Traders Daily
Jones Trading Initiates Coverage of Enliven Therapeutics (ELVN) with Buy Recommendation - MSN
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 By Investing.com - Investing.com South Africa
Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 - Investing.com
Enliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02 - MSN
Enliven Therapeutics CFO sells $24,422 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CFO sells $24,422 in stock - Investing.com
Enliven Therapeutics chief medical officer sells $24,482 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics chief medical officer sells $24,482 in stock - Investing.com India
Enliven Therapeutics COO Anish Patel sells $21,482 in stock - Investing.com
Enliven Therapeutics COO Anish Patel sells $21,482 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics' chief scientific officer sells $25,412 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CEO Kintz sells $27,722 in stock - Investing.com
Enliven Therapeutics' chief scientific officer sells $25,412 in stock - Investing.com India
Enliven Therapeutics director Heyman sells $47,104 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CEO Kintz sells $27,722 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics director Heyman sells $47,104 in stock - Investing.com India
Anish Patel Sells 716 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - MarketBeat
When (ELVN) Moves Investors should Listen - Stock Traders Daily
Enliven Therapeutics, Inc. (ELVN) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
ELVN stock soars to 52-week high, reaching $28.66 By Investing.com - Investing.com Australia
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 52-Week HighHere's Why - MarketBeat
Richard A. Heyman Sells 1,270 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - MarketBeat
Enliven Therapeutics Inc [ELVN] Insider Lyssikatos Joseph P sells 37,878 Shares - Knox Daily
Enliven Therapeutics Inc (ELVN) stock analysis: A simple moving average approach - US Post News
Financial Metrics Check: Enliven Therapeutics Inc (ELVN)’s Ratios for Trailing Twelve Months - The Dwinnex
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Update - MarketBeat
Enliven Therapeutics, Inc. Is a Great Choice for 'Trend' Investors, Here's Why - Benzinga
Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 10,420 Shares of Stock - MarketBeat
Enliven Therapeutics executive sells over $1.4 million in company stock - Investing.com India
Enliven Therapeutics director sells over $290k in company stock - Investing.com
Enliven Therapeutics director sells over $290k in company stock By Investing.com - Investing.com UK
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 5.6%What's Next? - MarketBeat
Enliven Therapeutics CFO sells over $300k in company stock By Investing.com - Investing.com South Africa
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):